Inozyme Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed Chief Operations Officer
BOSTON, April 04, 2023 (GLOBE NEWSWIRE) — Inozyme Pharma, Inc. (Nasdaq: INZY), a clinical-stage rare…
Year: 2023
Veru Announces Preclinical Results from Expanded Sabizabulin Program into Influenza-Induced Severe Acute Respiratory Distress Syndrome and Provides Update on COVID-19 Program
In the final report, sabizabulin significantly reduced key cytokines involved in Acute Respiratory Distress Syndrome…
Veru Announces Preclinical Results from Expanded Sabizabulin Program into Influenza-Induced Severe Acute Respiratory Distress Syndrome and Provides Update on COVID-19 Program
In the final report, sabizabulin significantly reduced key cytokines involved in Acute Respiratory Distress Syndrome…
SciSparc Receives Final Approval to Commence its Phase IIb Clinical Trial for SCI-110 to treat Tourette Syndrome
The Tel Aviv Sourasky Medical Center granted its final approval to use SCI-110 in a…
SciSparc Receives Final Approval to Commence its Phase IIb Clinical Trial for SCI-110 to treat Tourette Syndrome
The Tel Aviv Sourasky Medical Center granted its final approval to use SCI-110 in a…
Avid Bioservices Unveils Completed Mammalian Cell Facilities Expansion Providing Significantly Increased Capacity for Existing and Future Customers
Company to Host Open House to Celebrate Official Launch of Newest CGMP Mammalian Cell Manufacturing…
Avid Bioservices Unveils Completed Mammalian Cell Facilities Expansion Providing Significantly Increased Capacity for Existing and Future Customers
Company to Host Open House to Celebrate Official Launch of Newest CGMP Mammalian Cell Manufacturing…
Nexcella announces poster presentation at the European Society for Blood and Marrow Transplantation 49th Annual Meeting
Updated clinical data for NXC-201, a next-generation CAR-T for multiple myeloma and AL amyloidosis, will…
Nexcella announces poster presentation at the European Society for Blood and Marrow Transplantation 49th Annual Meeting
Updated clinical data for NXC-201, a next-generation CAR-T for multiple myeloma and AL amyloidosis, will…
Axial Therapeutics Announces Age Expansion in Global Phase 2b Clinical Trial for Irritability Associated with Autism Spectrum Disorder (ASD)
— Children aged 5 to 17 with autism are now eligible to enroll in the…
Axial Therapeutics Announces Age Expansion in Global Phase 2b Clinical Trial for Irritability Associated with Autism Spectrum Disorder (ASD)
— Children aged 5 to 17 with autism are now eligible to enroll in the…
Enlivex Announces Tislelizumab Clinical Collaboration, Full Year 2022 Financial Results, and Provides Business Updates
Clinical collaboration with BeiGene announced on April 3, 2023 to evaluate the safety and efficacy…
Enlivex Announces Tislelizumab Clinical Collaboration, Full Year 2022 Financial Results, and Provides Business Updates
Clinical collaboration with BeiGene announced on April 3, 2023 to evaluate the safety and efficacy…
Nexcella, an Immix Biopharma subsidiary, announces poster presentation at the European Society for Blood and Marrow Transplantation 49th Annual Meeting
Updated clinical data for NXC-201, a next-generation CAR-T for multiple myeloma and AL amyloidosis, will…
Nexcella, an Immix Biopharma subsidiary, announces poster presentation at the European Society for Blood and Marrow Transplantation 49th Annual Meeting
Updated clinical data for NXC-201, a next-generation CAR-T for multiple myeloma and AL amyloidosis, will…
Phathom Pharmaceuticals Announces Regulatory Update and Plans for 2023 Erosive Esophagitis and H. pylori Commercial Launch
Favorable feedback following meeting with the U.S. Food and Drug Administration (FDA) allows for planned…
Phathom Pharmaceuticals Announces Regulatory Update and Plans for 2023 Erosive Esophagitis and H. pylori Commercial Launch
Favorable feedback following meeting with the U.S. Food and Drug Administration (FDA) allows for planned…
Amarin Announces VAZKEPA® (Icosapent Ethyl) Approved by Israel’s Ministry of Health
— Approval of VAZKEPA® to Reduce the Risk of Cardiovascular (CV) Events in Adult Statin-Treated…
Amarin Announces VAZKEPA® (Icosapent Ethyl) Approved by Israel’s Ministry of Health
— Approval of VAZKEPA® to Reduce the Risk of Cardiovascular (CV) Events in Adult Statin-Treated…
Eckert & Ziegler to Supply POINT Biopharma with Actinium-225
BERLIN and INDIANAPOLIS, April 04, 2023 (GLOBE NEWSWIRE) — Eckert & Ziegler (ISIN DE0005659700, TecDAX)…